• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

    2/1/23 5:00:16 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTVT alert in real time by email

    HIGH POINT, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Elizabeth (Betzy) Keiley as Executive Vice President and General Counsel, effective immediately.

    "We welcome Betzy to vTv. Her years of legal expertise and deep experience in life sciences will be valuable to the vTv team," said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics. "Her decades of experience in both private practice and corporate settings make her an ideal fit for this position. I am confident that we will benefit from her contributions and look forward to working closely with her as we move ahead toward our long-term capital funding goals and launching our phase 3 clinical trials."

    Ms. Keiley is an accomplished life science industry attorney who has served in multiple senior-level legal positions at publicly traded biotechnology, diagnostic and medical device companies. She joins vTv from Entasis Therapeutics Holdings Inc., where she served as General Counsel. Prior to Entasis, she was Senior Vice President, General Counsel at Oxford Immunotec, where she simultaneously served for seven years as Chief Compliance Officer, and was Assistant General Counsel, Americas, of Zimmer, Inc., a subsidiary of Zimmer Holdings, Inc. Before beginning her corporate career in 2008, Ms. Keiley was a partner at Wildman, Harrold, Allen & Dixon LLP in Chicago, Illinois, where she focused on a wide range of corporate and commercial matters for clients in a variety of industries, including medical devices. Ms. Keiley earned her bachelor's degree in Psychology and Philosophy from Boston College and a J.D. from Loyola University School of Law.

    "With the upcoming initiation of our pivotal studies of TTP399, the company is approaching a key inflection point with the potential to become a commercial organization in the coming years," added Ms. Keiley. "I am eager to put my skills and expertise to work as we continue to advance the development of TTP399 toward our ultimate goal of changing the treatment paradigm for patients with T1D."

    About vTv Therapeutics

    vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and cystic fibrosis related diabetes. vTv's development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease, renal disease, primary mitochondrial myopathy, and pancreatic cancer. For more information, please visit www.vtvtherapeutics.com.

    Forward-Looking Statements

    The statements made in this release may include forward-looking statements regarding (i) diabetes market and other markets, (ii) the development and clinical trial process, regulatory approval process and attributes of investigational and marketed products to treat these diseases and other conditions, and (iii) the future operations, fund-raising activities, expenditures, opportunities and financial performance of vTv Therapeutics Inc.

    These forward-looking statements are only estimates based upon the information available to vTv Therapeutics Inc. (or the party preparing such forward-looking statements) as of the date of this release. The forward-looking statements included herein involve known and unknown risks and uncertainties and other important factors such that actual future operations, opportunities, product development processes and outcomes, clinical trial processes and outcomes, regulatory approval processes and outcomes, economic performance of products, fund-raising activities and financial performance may differ materially from those set forth in or implied in these forward-looking statements. These risks, uncertainties, and other factors, which may not be within our control, are discussed in more detail in our quarterly and annual reports filed with the Securities and Exchange Commission, including, without limitation, under the captions, "Risk Factors," "Cautionary Note Regarding Forward-Looking Statements" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." Therefore, you should read this release in conjunction with such meaningful cautionary statements.

    Undue reliance should not be placed on forward-looking statements, which speak only as of the date hereof. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statements.

    This release is being provided to you for information purposes only. This release does not constitute an offer or sale of (or the solicitation of an offer to buy) any securities of vTv Therapeutics Inc. or any of its subsidiaries.

    This release should not be relied upon for making any investment decision with respect to any securities of vTv Therapeutics Inc. or any of its subsidiaries. Any investment decision made with respect to any such securities should be based solely on an offering document relating to such securities (if any), including the information incorporated by reference therein.

    Contacts:

    Investors:

    Lee Roth

    Burns McClellan

    [email protected]

    Media:

    Selina Husain / Robert Flamm, Ph.D.

    Burns McClellan, Inc.

    [email protected] / [email protected]



    Primary Logo

    Get the next $VTVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VTVT

    DatePrice TargetRatingAnalyst
    2/18/2022$5.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $VTVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Akkaraju Srinivas

      4 - vTv Therapeutics Inc. (0001641489) (Issuer)

      4/24/25 4:40:29 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Pres, CEO and Exec Chairperson Sekhri Paul J

      4 - vTv Therapeutics Inc. (0001641489) (Issuer)

      3/7/25 4:20:26 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Samsara Biocapital Gp, Llc disposed of 58,836 shares (SEC Form 4)

      4 - vTv Therapeutics Inc. (0001641489) (Issuer)

      12/6/24 4:15:18 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on vTv Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of vTv Therapeutics with a rating of Overweight and set a new price target of $5.00

      2/18/22 6:42:27 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

      Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2024, and provided an update on recent corporate de

      3/20/25 5:35:31 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

      Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months HIGH POINT, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that the United States Food and Drug Administration (FDA) has lifted the clinical hold on the cadisegliatin clinical program, which includes

      3/17/25 8:30:00 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

      WESTON, Fla., Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Cantex's azeliragon for the treatment of brain metastasis from breast cancer. This new azeliragon designation adds to azeliragon's two other Orphan Drug Designations for the treatment of pancreatic cancer and glioblastoma, received in mid-2024 and early 2023, respectively.

      12/9/24 7:33:00 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres, CEO and Exec Chairperson Sekhri Paul J bought $83,812 worth of shares (5,000 units at $16.76) (SEC Form 4)

      4 - vTv Therapeutics Inc. (0001641489) (Issuer)

      11/19/24 4:31:06 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Financials

    Live finance-specific insights

    See more
    • vTv Therapeutics Announces Investment by CinRx Pharma

      HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC ("CinPax"), a subsidiary of CinRx Pharma, LLC ("CinRx"). Under the terms of the agreements, CinPax acquired 4,154,549 shares of Class A Common Stock of vTv at an issue price of approximately $2.41 per share, with $6 million paid in cash at closing, and the remaining amount of $4 million payable on November 22, 2022. The agreements also provide for the issuance of 1.2 million warrants to CinRx to acquire additional shares of Class A Common Stock that become exercisable upon agreed vesting triggers (including FDA ap

      7/25/22 7:00:00 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    SEC Filings

    See more
    • SEC Form 144 filed by vTv Therapeutics Inc.

      144 - vTv Therapeutics Inc. (0001641489) (Subject)

      5/1/25 4:28:23 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by vTv Therapeutics Inc.

      DEF 14A - vTv Therapeutics Inc. (0001641489) (Filer)

      4/25/25 4:20:08 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • vTv Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - vTv Therapeutics Inc. (0001641489) (Filer)

      3/31/25 4:30:12 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Leadership Updates

    Live Leadership Updates

    See more
    • vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

      Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2024, and provided an update on recent corporate de

      3/20/25 5:35:31 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

      HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments. "Our newly appointed Chief Medical Officer, Dr. Thomas Strack, who has been working with us on a consulting basis for several months, is now leading our work on the cadisegliatin Phase 3 program with the goal of initiating studies as soon as possible," said Paul Sekhri, Chief Executive Offi

      11/9/23 4:30:00 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

      HIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced the appointment of Thomas Strack, M.D. as Chief Medical Officer, effective immediately. "I am pleased to welcome Dr. Strack to the vTv team," said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics. "He brings extensive drug development and clinical expertise, as well as a wealth of knowledge in endocrine, metabolic, and cardiovascular diseases. We believe his expertise will be invaluable as

      11/2/23 8:00:54 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by vTv Therapeutics Inc.

      SC 13G - vTv Therapeutics Inc. (0001641489) (Subject)

      11/12/24 10:40:28 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by vTv Therapeutics Inc. (Amendment)

      SC 13D/A - vTv Therapeutics Inc. (0001641489) (Subject)

      3/22/24 4:57:31 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by vTv Therapeutics Inc.

      SC 13D - vTv Therapeutics Inc. (0001641489) (Subject)

      3/5/24 7:52:29 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care